- Home
- VTYX vs ATLC Comparison
VTYX vs ATLC Comparison
Compare VTYX & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VTYX | ATLC |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | 417 |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 824.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTYX | ATLC |
|---|---|---|
| Price | $13.99 | $56.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $13.50 | ★ $87.50 |
| AVG Volume (30 Days) | ★ 3.4M | 51.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $402.57 |
| Revenue Next Year | N/A | $60.95 |
| P/E Ratio | ★ N/A | $9.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $41.68 |
| 52 Week High | $15.34 | $78.91 |
Technical Indicators
Market Signals| Indicator | VTYX | ATLC |
|---|---|---|
| Relative Strength Index (RSI) | 72.58 | 52.70 |
| Support Level | $13.89 | $52.78 |
| Resistance Level | $14.07 | $58.81 |
| Average True Range (ATR) | 0.03 | 2.80 |
| MACD | -0.11 | 0.55 |
| Stochastic Oscillator | 88.89 | 68.27 |
Price Performance
Historical ComparisonAbout VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.